E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise) |
|
E.1.1.1 | Medical condition in easily understood language |
Antibody deficency not caused by another medical condition, such as cancer or infection, or immunosupressive or chemotherapeutic therapy. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Immune System Diseases [C20] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Difference in mean AD and ILD scores (as measured with CT scanning) between t=0 and t=2 years in patients with standard vs higher Ig replacement therapy dosing.
|
|
E.2.2 | Secondary objectives of the trial |
1. The incidence of symptomatic lower pulmonary infections in PAD patients with high Ig replacement therapy dosing versus standard Ig replacement therapy dosing. 2. Number of physician diagnosed lower respiratory tract infections in patients with high vs standard Ig replacement therapy dosing. 3. Number of hospital admissions and duration of hospital admissions for pulmonary complications (ao exacerbations of bronchiectasis) 4. Outcomes of pulmonary function tests (specifically: Total Lung Capacity (TLC), Forced Expiratory Volume after 1 second (FEV1), CO diffusion) on t=0 and t=2 years in all patients 5. Days missed from work / school in patients with high vs standard Ig replacement therapy dosing. 6. Total therapeutic and preventive costs
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
In order to be eligible to participate in this study, a subject must meet all of the following criteria: 1. Age 4-60 years 2. Diagnosis of Primary Antibody Deficiency / Common Variable Immunodeficiency Disorder (see Appendix 1). 3. Indication for immunoglobulin replacement therapy and/or treated with immunoglobulin replacement therapy 4. Current IgG dosing 0.4 - 0.6 gr / kg / 3-4 weeks 5. Receiving treatment and follow up for PAD by one of the physicians in the participating centers 6. Written informed consent 7. Normal lung status, or mild to medium severe pulmonary disease (measured by pulmonary function test and on CT scan, scored by an independent radiologist based on the following criteria): a. Baseline AD score < 5 and ILD score < 7, or; b. Baseline AD score > 5 and/or ILD score > 7 without clinical diagnosis of severe respiratory insufficiency (defined as: saturations in room air <92% and / or oxygen dependency). c. Baseline pulmonary function (FEV1 and FVC >70% expected for age and body weight / length)
|
|
E.4 | Principal exclusion criteria |
A potential subject who meets any of the following criteria will be excluded from participation in this study: 1. Age above 60 year 2. Diagnosis of Combined Immunodeficiency (CID) disease at onset of study (see Appendix A). Explanation: Combined Immunodeficiency is featured by the occurrence of more viral infections and reactivations and thus less comparable to PAD. 3. Severe pulmonary disease, determined by an independent radiologist: a. Baseline AD score > 5 and/or ILD score > 7, in combination with: i. Saccular bronchiectasis on CT scan, or; ii. Clinical diagnosis of severe respiratory insufficiency (defined as: (defined as: saturations in room air <92%, and/ or oxygen dependency). b. Baseline pulmonary function (FEV1 and FVC >70% expected for age and body weight / length)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The main outcome parameters of this study are rate of progression of AD an ILD after 24 months in patients receiving a higher dose of Ig medication versus patients receiving standard Ig dosing, and the associated decrease in health costs. To measure this main outcome parameter we will use a disease specific CT scoring method that was developed and validated specifically for monitoring of lung disease in PAD (9,10). The scoring method was shown to be accurate and reproducible. By protocol, CT scans are made at t = 0 and t = 2 years. It is however possible that clinical symptoms or situations arise during the study period within a participant, so that an additional CT scan is indicated. The reasons for making an extra CT scan (following current clinical practice guidelines) are: − Symptoms of dyspnea accompanied by low saturations (<92%) − A lung function (FVC or FEV1) below 80% of expected value for age and length / body weight − Abnormalities on a chest X-ray making a CT scan necessary (made for indications of extensive coughing, pain with breathing, or dyspnea for unknown reasons)
If an extra CT scan is made, this may lead to an adjustment of clinical treatment (in which situation routine clinical guidelines will be followed). Any additional CT scans (apart from t=0 or t=2 years) will be evaluated during the analysis presented to the DSMB / DMB after one year. It is our experience that extra CT scanning is an unusual event in these patients. We thus expect a low number of additional CT scans. We thus expect that findings on additional CT scans will not lead to premature termination of the study. The CT scan at t = 2 years must in principle be performed. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
At baseline and after 2 years |
|
E.5.2 | Secondary end point(s) |
1. Number of upper- and lower respiratory tract infections before onset of study and during study, i.e.: Sino pulmonary disease, otitis, pneumonia, collected by study CRF’s. 2. Pulmonary symptoms will be evaluated on a daily basis (during two periods of 2 months) using a diary that can be directly entered in Castor. 3. Days missed from school and work due to infections, measured by the PCQ (productivity cost questionnaire) instrument. 4. Quality of life, measured with the EQ-5D questionnaire 5. Ig dosing and IgG trough levels in intervention and in control group 6. Total health costs (consisting of costs for health care professional visits, medication, hospitalizations, imaging and biochemical investigations) in intervention and control group, collected from electronic patient files. 7. Immunological laboratory phenotype, collected from electronic patient files. 8. Adverse events: reporting and monitoring of patients and Adverse Events (AEs), Serious Adverse Events (SAEs) and Suspected Unexpected Serious Adverse Reaction (SUSARs) will be done by an independent monitor. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Point 1 and 8 will be measured continiously. Point 2 will be evaluated during two periods of 2 months. Point 3,4 and 7 will be evaluated at baseline, after 12 months and after 24 months. Point 5 will be evaluated at baseline, after 1 month, after 2 months, after 6 months, after 8 months, after 12 months and after 24 months Point 7 will be evaluated at the end of the study |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Patients who do not receive a 33% dose increase of immunoglobuline replacement therapy |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 3 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |